Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
4SC AG (VSC) - Financial and Strategic SWOT Analysis Review
Publication Date Aug 2011
Publisher GlobalData
Product Type Report
Pages 39
Single User License $ 125.00
Site User License $ 250.00
Corporate User License $ 375.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

4SC AG (VSC) - Financial and Strategic SWOT Analysis Review

Summary

4SC AG is a Germany based research oriented company which concentrates mainly on the discovery of the drugs as well as its development. The main focus of the research is centered on cancer and autoimmune indications. 4SC develops drug candidates until proof-of-concept in order to generate value creating partnerships with the pharmaceutical industry in return for advance and milestone payments as well as royalties. It collaborates with AiCuris in the field of antiviral and antibacterial drug discovery, with ProQinase to identify a new generation of protein kinase inhibitors in order to develop anticancer drugs, with and ViroLogik in the field of developing, manufacturing and market the compound for viral diseases. The company is having 91 employees till 2009 and it is headquartered in Martinsried, Germany.

4SC AG Key Recent Developments…

May 10, 2011: 4SC Reports Net Loss Of €4.7m For Q1 2011
May 26, 2010: Phase Ii Hodgkin Lymphoma Study With Hdac Inhibitor Resminostat Advances Into The Second Recruitment Stage
Apr 16, 2010: 4SC And Nexigen Receive EUR 1.4 Million Funding From German Federal Ministry Of Education And Research
Feb 11, 2010: 4sc Announces Treatment Of First Patient In A Phase I Study Of 4sc-205
Jan 21, 2010: 4SC Initiates Dosing In First-in-Man Phase I 4SC-203 Study

This comprehensive SWOT profile of 4SC AG provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.


Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Section 1 - About the Company 5
4SC AG - Key Facts 5
4SC AG - Key Employees 6
4SC AG - Key Employee Biographies 7
4SC AG - Major Products and Services 8
4SC AG - Pharmaceutical Pipeline Products Data 9
4SC AG, Pipeline Products by Therapy Area 9
4SC AG, Pipeline Products by Development Phase 10
4SC AG - History 12
4SC AG - Company Statement 13
4SC AG - Locations And Subsidiaries 15
Head Office 15
Section 2 – Company Analysis 16
4SC AG - Business Description 16
4SC AG - SWOT Analysis 18
SWOT Analysis - Overview 18
4SC AG - Strengths 18
Strength - Intellectual Property 18
Strength - 4SCan Technology 18
4SC AG - Weaknesses 18
Weakness - Declining Market Share in Sector 18
Weakness - Lack of manufacturing facilities 18
4SC AG - Opportunities 19
Opportunity - Market Potential: Cancer 19
Opportunity - Focused R&D activities 19
Opportunity - Treatment for Rheumatoid Arthritis 19
4SC AG - Threats 19
Threat - Industry Consolidation 19
Threat - Uncertain R&D Outcomes 19
Threat - Growing Parallel Trade 20
4SC AG - Key Competitors 21
Section 3 – Company Financial Ratios 22
Financial Ratios - Capital Market Ratios 22
Financial Ratios - Annual Ratios 22
Performance Chart 24
Financial Performance 24
Financial Ratios - Interim Ratios 25
Financial Ratios - Ratio Charts 26
Section 4 – Company’s Lifesciences Financial Deals and Alliances 27
4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011 27
4SC AG, Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011 28
4SC AG, Recent Deals Summary 29
Section 5 – Company’s Recent Developments 30
May 10, 2011: 4SC Reports Net Loss Of €4.7m For Q1 2011 30
May 26, 2010: Phase Ii Hodgkin Lymphoma Study With Hdac Inhibitor Resminostat Advances Into The Second Recruitment Stage 31
Apr 16, 2010: 4SC And Nexigen Receive EUR 1.4 Million Funding From German Federal Ministry Of Education And Research 31
Feb 11, 2010: 4sc Announces Treatment Of First Patient In A Phase I Study Of 4sc-205 31
Jan 21, 2010: 4SC Initiates Dosing In First-in-Man Phase I 4SC-203 Study 32
Jan 12, 2010: 4sc Announces First Patient Treated In A Phase Ii Hodgkin’s Lymphoma Study With Hdac Inhibitor Resminostat (4sc-201) 33
Jan 11, 2010: 4SC Initiates Treatment In Phase II Study Evaluating Resminostat 33
Section 6 – Appendix 35
Methodology 35
Ratio Definitions 35
About GlobalData 39
Contact Us 39
Disclaimer 39
List of Tables
4SC AG, Key Facts 5
4SC AG, Key Employees 6
4SC AG, Key Employee Biographies 7
4SC AG, Major Products and Services 8
4SC AG, Number of Pipeline Products by Therapy Area 9
4SC AG, Number of Pipeline Products by Development Stage 10
4SC AG, Pipeline Products By Therapy Area and Development Phase 11
4SC AG, History 12
4SC AG, Key Competitors 21
4SC AG, Ratios based on current share price 22
4SC AG, Annual Ratios 22
4SC AG, Interim Ratios 25
4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011 27
4SC AG, Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011 28
4SC AG, Recent Deals Summary 29
Currency Codes 35
Capital Market Ratios 35
Equity Ratios 36
Profitability Ratios 36
Cost Ratios 37
Liquidity Ratios 37
Leverage Ratios 38
Efficiency Ratios 38
List of Figures
4SC AG, Pipeline Products by Therapy Area 9
4SC AG, Pipeline Products by Development Phase 10
4SC AG, Performance Chart (2006 - 2010) 24
4SC AG, Ratio Charts 26
4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011 27
4SC AG, Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011 28

Title Date Price
3DM Inc. - Strategic SWOT Analysis Review
By GlobalData
3DM Inc. - Strategic SWOT Analysis ReviewSummary3DM Inc. (3DM) is a privately held specialty biomaterials and medical device company. It is a subsidiary of 3D-Matrix, Ltd, Japan. The company develops ...Read More
Aug 2011 $125.00
3M ESPE Dental Products Market Share Analysis
By GlobalData
3M ESPE Dental Products Market Share AnalysisSummaryGlobalData’s new report, “3M ESPE Dental Products Market Share Analysis” provides in-depth information on 3M ESPE Dental Products’s market p ...Read More
Feb 2013 $1000.00
3M Health Care - Strategic SWOT Analysis Review
By GlobalData
3M Health Care - Strategic SWOT Analysis ReviewSummary3M Health Care, a business segment of 3M Company, provides medical and oral care products, drug delivery and health information systems worldwide. ...Read More
Aug 2011 $125.00
3SBio Inc. (SSRX) - Financial and Strategic SWOT Analysis Review
By GlobalData
Summary3SBio Inc. (3S Bio) is a biotechnology company with focus on the research and development, manufacturing and marketing of biopharmaceutical products in China. It develops recombinant, or geneti ...Read More
Apr 2013 $125.00
3Shape A/S. Market Share Analysis
By GlobalData
3Shape A/S. Market Share AnalysisSummaryGlobalData’s new report, “3Shape A/S. Market Share Analysis” provides in-depth information on 3Shape A/S.’s market position in the CAD/CAM dental system ...Read More
Nov 2012 $1000.00
3WIN nv - Product Pipeline Analysis
By GlobalData
3WIN nv - Product Pipeline AnalysisSummary3WIN nv (3WIN) is engaged in the development and marketing of active implantable medical devices. The company is developing a deep brain stimulator (DBS), whi ...Read More
Oct 2011 $750.00
4SC AG (VSC) - Financial and Strategic SWOT Analysis Review
By GlobalData
4SC AG (VSC) - Financial and Strategic SWOT Analysis ReviewSummary4SC AG is a Germany based research oriented company which concentrates mainly on the discovery of the drugs as well as its development ...Read More
Aug 2011 $125.00
572-Trii (HIV) - Forecast and Market Analysis to 2022
By GlobalData
572-Trii (HIV) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “572-Trii (HIV) - Forecast and Market Analysis to ...Read More
Mar 2013 $3995.00
A&G Pharmaceutical, Inc. - Product Pipeline Analysis
By GlobalData
SummaryA&G Pharmaceutical, Inc. (A&G) is a pharmaceutical company, based in the US. The company develops therapeutic and diagnostic products for the in-vitro diagnostic markets. Its products include b ...Read More
Nov 2012 $750.00
A-dec Inc. GmbH Market Share Analysis
By GlobalData
A-dec Inc. GmbH Market Share AnalysisSummaryGlobalData’s new report, “A-dec Inc. GmbH Market Share Analysis” provides in-depth information on A-dec Inc..’s market position in the dental device ...Read More
Jan 2013 $1000.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   
   
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9425069161
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z